Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

18.50
-1.7700-8.73%
Post-market: 18.500.00000.00%18:11 EDT
Volume:3.78M
Turnover:70.80M
Market Cap:1.78B
PE:-3.17
High:19.40
Open:19.36
Low:18.29
Close:20.27
52wk High:42.37
52wk Low:18.29
Shares:96.48M
Float Shares:92.79M
Volume Ratio:1.60
T/O Rate:4.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8316
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-22.03%
PB:-22.31
PE(LYR):-3.17

Loading ...

Ultragenyx Cuts 10% of Workforce, Targets Profitability in 2027

Dow Jones
·
Feb 13

Earnings Flash (RARE) Ultragenyx Pharmaceutical Posts Q4 Revenue $207M, vs. FactSet Est of $198.6M

MT Newswires Live
·
Feb 13

Ultragenyx Q4 revenue rises 25% amid restructuring

Reuters
·
Feb 13

Ultragenyx Pharmaceutical Q4 EPS $(1.29) Misses $(1.14) Estimate, Sales $207.000M Beat $196.971M Estimate

Benzinga
·
Feb 13

Ultragenyx posts Q4 2025 product sales of USD 102 million, up 42 percent

Reuters
·
Feb 13

BRIEF-Ultragenyx Q4 EPS USD -1.29

Reuters
·
Feb 13

Ultragenyx Q4 Operating Expenses USD 321 Million

THOMSON REUTERS
·
Feb 13

Ultragenyx Pharmaceutical Inc - in 2026, Combined R&D and SG&a Expenses Are Expected to Be Flat to Down Low-Single Digits Versus 2025

THOMSON REUTERS
·
Feb 13

Ultragenyx Pharmaceutical Inc - Announces 10% Workforce Reduction

THOMSON REUTERS
·
Feb 13

Ultragenyx Pharmaceutical Inc - Workforce Reduction Impacts Approximately 130 Employees

THOMSON REUTERS
·
Feb 13

Ultragenyx Pharmaceutical Inc - 2026 Total Revenue From Current Products Expected to Be Between $730 Mln to $760 Mln

THOMSON REUTERS
·
Feb 13

Ultragenyx Pharmaceutical Inc - in 2027, R&D Expenses Are Expected to Decrease From 2025 Levels by 38%, or Approximately $280 Mln

THOMSON REUTERS
·
Feb 13

Ultragenyx Pharmaceutical Inc FY2026 REV View $786.9 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
Feb 13

Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

GlobeNewswire
·
Feb 13

Ultragenyx Faces Securities Class Action Over Alleged Misleading Statements

Reuters
·
Feb 12

Ultragenyx Faces Securities Fraud Class Action Over Failed Drug Trials

Reuters
·
Feb 10

How UX111’s FDA Resubmission and First-in-Disease Potential Will Impact Ultragenyx Pharmaceutical (RARE) Investors

Simply Wall St.
·
Feb 10

Ultragenyx Pharmaceutical Inc. to Host Conference Call for Financial Results and Corporate Update

Reuters
·
Feb 06

Ultragenyx Faces Investor Lawsuit Over Alleged Misleading Statements on Drug Trial Results

Reuters
·
Feb 05

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Pfizer (PFE)

TIPRANKS
·
Feb 04